Zydus Lifesciences Ltd. NSE: ZYDUSLIFE | BSE: 532321

Strong Performer, Getting Expensive

Download real time

1011.95 3.75 (0.37%)

27.29% Gain from 52W Low

1.1M

NSE+BSE Volume

NSE 04 Sep, 2025 3:31 PM (IST)

Zydus Lifesciences Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Zydus Lifesciences Ltd. from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

16 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Acquisition of stake up to 11.86% of the paid-up equity share capital of AMP Energy Green Nine Private Limited.

Zydus Lifesciences Ltd.

14 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets

Zydus Lifesciences Ltd.

10 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - USFDA Inspection

BSE India

We hereby inform that the USFDA inspected the Company's injectable facility at Jarod, Gujarat from 24th February to 10th March, 2022. At the end of the inspection, three observations are issued.

Zydus Lifesciences Ltd.

09 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press release dated March 9, 2022 titled 'Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets'.

Zydus Lifesciences Ltd.

08 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY(tm) (Fosdenopterin)

Zydus Lifesciences Ltd.

07 Mar 2022

1011.95

0.37%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD)

Zydus Lifesciences Ltd.

28 Feb 2022

1011.95

0.37%

Company Update

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of …

BSE India

Intimation of revised MOA and AOA of the Company, pursuant to change in the name of the Company.

Zydus Lifesciences Ltd.

25 Feb 2022

1011.95

0.37%

Company Update

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication of Notice of name change of the Company

Zydus Lifesciences Ltd.

24 Feb 2022

1011.95

0.37%

Cadila Healthcare changes name to Zydus Lifesciences Limited

Business Standard

Unveils 'innovation and care' centric corporate brand identity

Deven Choksey increased Buy price target of Zydus Lifesciences Ltd. to 1183.0 on 25 Aug, 2025.

Zydus Lifesciences Ltd.

24 Feb 2022

1011.95

0.37%

Company Update

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Change of Company Name

BSE India

Name of the Company is changed from Cadila Healthcare Limited to Zydus Lifesciences Limited.

Is Cadila Healthcare Ltd. worth buying?

856 Votes:

Buy 81.78%

Sell 9.93%

Hold 8.29%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >